Document is current
Any future updates will be listed below
-
Authors
Szeszko, Philip R. https://orcid.org/0000-0002-6383-6142
Kowalchyk, Mary
Chu, King-Wai
Aladin, Sana
Dolgopolskaia, Elen-Sarrah
Ng, Sabrina
Hollander, Sean https://orcid.org/0000-0003-2363-8173
Perez-Rodriguez, M. Mercedes https://orcid.org/0000-0001-5137-1993
McClure, Margaret M.
Kahn, René S. https://orcid.org/0000-0001-5909-8004
Chan, Chi C.
Haznedar, M. Mehmet
Goldstein, Kim E.
Fleysher, Lazar
Hazlett, Erin A.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01 MH121411, R01 MH121411)
- License Information
-
More Information
Article History
Received: 11 August 2024
Revised: 9 May 2025
Accepted: 29 May 2025
First Online: 7 June 2025
Competing interests
: Dr. Perez-Rodriguez has received research grant funding from Neurocrine Biosciences (Inc), Millennium Pharmaceuticals, Takeda, Merck, and AI Cure and is an Advisory Board member for Neurocrine Biosciences, Inc. None of the other authors report any financial conflicts.
: This study was approved by the Institutional Review Board of the Icahn School of Medicine at Mount Sinai (IRB No. 20-00068) and all methods were performed in accordance with relevant guidelines and regulations. Written informed consent was obtained from all the participants.
